Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
MORRIS PLAINS, N.J., July 16, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU),a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...
-
-- Repeated Cycles of 90Y-Clivatuzumab Treatments Extended Survival When Compared to Single Cycle -- -- Low-Dose Gemcitabine in Combination with 90Y-Clivatuzumab Significantly Improved...
-
MORRIS PLAINS, N.J., June 14, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...
-
MADRID, Spain, June 13, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...
-
• Relative to the 12-week, double-blind EMBLEM™ study, primary outcome data from the open-label extension identified no new safety or tolerability signals1 • Relative to...
-
Immunomedics Reports Progress With Labeling Proteins, Including Antibodies, for Improved PET Imaging
VANCOUVER, British Columbia, June 12, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products...
-
VANCOUVER, British Columbia, June 11, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU),a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products...
-
VANCOUVER, British Columbia, June 10, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products...
-
-- Pretargeting System Allows Dual Nuclear/Fluorescence Imaging During Cancer Surgery -- -- Results Reported at SNMMI 2013 Annual Meeting -- VANCOUVER, British Columbia, June 10, 2013 (GLOBE...
-
MORRIS PLAINS, N.J., June 10, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...